 | Battling Bias in Boston Biotech A survey of seven MIT science and engineering departments quantifies how many biotech startups have been lost to gender bias: 40. The study, which compared the relative proportion of female faculty members (22%) to woman-founded companies (10%), got its start at the 2018 Xconomy Prize gala. Nancy Hopkins—no stranger to measuring gender bias—told the story of a woman in venture capital who carried a list of 100 VC-funded Boston biotechs, 99 of which were founded by men. Hopkins’s KI colleagues Sangeeta Bhatia, entrepreneur and founder of Glympse Bio, and MIT President Emerita Susan Hockfield heard the speech and joined with Hopkins to brainstorm strategies for addressing this imbalance. Their conversation grew into the Boston Biotech Working Group, which carried out the survey and is spearheading several programs to boost the number of women biotech founders. |
|
Trip the Light Fan-gastric The Langer and Traverso Labs developed a light-sensitive hydrogel for gastrointestinal devices. Devices made with the gel break down when triggered by an ingestible LED, eliminating the need for surgical removal. The work, published in Science Advances, has numerous applications for long-term drug delivery, monitoring, and sensing. |
|
|
mTOR de Force Congratulations to KI member David Sabatini who, along with the University of Basel’s Michael Hall, has been honored with the Sjöberg Prize from the Royal Swedish Academy of Sciences and the BBVA Foundation’s Frontiers of Knowledge Award in Biology and Biomedicine for their discovery of the protein kinase mTOR. As a growth regulator, mTOR plays an important role in the development of cancer; the pair’s work, therefore, could pave the way for new cancer treatments. The Sabatini Lab’s recent review article in Nature Reviews Molecular Cell Biology examines the mTOR pathway’s influence on nutrition, growth, aging, and disease. |
|
|
Niche Interest The Hynes Lab sheds light on how metastatic tumor cells adapt to survive in different locations. Analysis of the extracellular matrix (ECM) surrounding breast cancer metastases, published in Cancer Research, revealed that tumor and local cells each contribute different proteins to create ECM niches that vary from organ to organ. |
|
|
Personalized Medicine and Medleys Meet Swarna Jeewajee, MIT senior, soprano, and aspiring physician-scientist. She balances her work in the Hemann Lab researching therapeutic vulnerabilities in near-haploid leukemia with her a capella group Singing for Service, which performs in nursing homes and rehabilitation centers throughout the Boston area. Her passion for patient-centered medicine is informed both by her experiences as an MIT student and by her own medical history, growing up in Mauritius with a poorly understood hearing loss and a transformative surgery to correct it in 2018. |
|
|
Syros Begins CDK7 Inhibitor Trial Syros Pharmaceuticals, co-founded by Bridge Project collaborators Richard Young and Nathanael Gray, has launched a Phase 1 trial of SY-5609. Potent and highly selective, the drug has broad applicability across a range of cancers, including resistant and hard-to treat tumors. It targets the CDK7 gene to combat increased oncogene expression and uncontrolled cell cycle progression. |
|
|
|
| | | | |
|
